Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-07), EuroEyes International Eye Clinic's Beta is 0.3853.
EuroEyes International Eye Clinic (HKSE:01846) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
EuroEyes International Eye Clinic Beta Related Terms
EuroEyes International Eye Clinic Beta Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, EuroEyes International Eye Clinic's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EuroEyes International Eye Clinic Beta vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, EuroEyes International Eye Clinic's Beta distribution charts can be found below:
* The bar in red indicates where EuroEyes International Eye Clinic's Beta falls into.
EuroEyes International Eye Clinic Beta Calculation
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
EuroEyes International Eye Clinic (HKSE:01846) has a Beta of 0.3853 as of Jul. 07, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for EuroEyes International Eye Clinic and its competitors.
Is EuroEyes International Eye Clinic's Beta too high?
EuroEyes International Eye Clinic's current Beta is 0.3853. Overall, EuroEyes International Eye Clinic has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EuroEyes International Eye Clinic's Beta compare to HCA and THC?
EuroEyes International Eye Clinic's Beta of 0.3853 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Healthcare Providers & Services company?
A good Beta depends on the Healthcare Providers & Services industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for EuroEyes International Eye Clinic and its competitors. EuroEyes International Eye Clinic's current Beta is 0.3853. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EuroEyes International Eye Clinic stock overvalued right now?
Based on GuruFocus' analysis, EuroEyes International Eye Clinic (HKSE:01846) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$5.52, compared to a current price of HK$2.40 — trading 56.5% below its estimated fair value. The current Beta is 0.3853. EuroEyes International Eye Clinic's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For EuroEyes International Eye Clinic (HKSE:01846), the current Beta is 0.3853 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EuroEyes International Eye Clinic (HKSE:01846) Overvalued in 2026?
Based on GuruFocus' analysis, EuroEyes International Eye Clinic stock appears to be undervalued.
The current stock price of HK$2.40 is trading 56.5% below its estimated GF Value™ of HK$5.52.
GuruFocus considers EuroEyes International Eye Clinic to be Significantly Undervalued.
Key valuation signals for HKSE:01846:
Beta: 0.3853
GF Value™: HK$5.52 vs. price of HK$2.40 (56.5% below fair value)
No single metric tells the full story. See the HKSE:01846 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EuroEyes International Eye Clinic Business Description
EuroEyes International Eye Clinic Ltd is principally engaged in the provision of vision correction services in Germany, Denmark, the UK, the PRC including Hong Kong, and Switzerland. The Group is a high-end vision correction service provider in Germany, PRC, the UK, Denmark, and Switzerland. Its vision correction services include refractive laser surgery, phakic lens surgery (ICL), lens exchange surgery, and others including PRK/LASEK and ICRS implantation. Its revenue categories include provision of vision correction services generate maximum revenue, training services, sales of pharmaceutical products and others. The Group's five reportable segments are Germany generate maximum revenue, Denmark, UK, Chinese Mainland, and Switzerland.
84GF Score
Get the complete analysis for HKSE:01846
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01846 has been successfully added to your 
